Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

PRLD

Prelude Therapeutics Inc

Pharmaceutical Preparations · SIC 2834CIK 1678660Held by 4 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$12.0M
Net Income FY2025
$(99.0M)
EPS (Basic, as reported)
$-1.29
Net Margin FY2025
-819.6%
ROE FY2025
-145.0%
Total Equity
$69.0M
Shares Out
80M
Business description

Prelude Therapeutics Inc — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 7 → 12 +71.4% CAGR
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue—————712
Research & development(24)(48)(87)(93)(103)(118)(94)
General & administrative(4)(11)(27)(31)(29)(29)(22)
Total operating expenses(28)(59)(114)(124)(132)(147)(117)
Operating income(28)(59)(114)(124)(132)(140)(105)
Other income (expense), net122810135
Income tax expense—————00
Net income(28)(57)(112)(115)(122)(127)(99)
EPS — basic——($2.43)($2.44)($2.02)($1.68)($1.29)
EPS — diluted——($2.43)($2.44)($2.02)($1.68)($1.29)
Shares outstanding — basic (M)——4647607677
Shares outstanding — diluted (M)——4647607677

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.